Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis
Approved adjuvant treatment options for stage III melanoma are the immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab, and in presence of a BRAF V600E/K mutation additionally dabrafenib in combination with trametinib (BRAFi/MEKi). This study aims to describe prescription patterns and rec...
Main Authors: | Michèle Hoffmann, Stefanie Hayoz, Berna C. Özdemir |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-7737/11/3/422 |
Similar Items
-
Comparative analysis of adjuvant therapy for stage III BRAF‐mut melanoma: A real‐world retrospective study from single center in China
by: Jingqin Zhong, et al.
Published: (2023-05-01) -
Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland
by: Ramon Staeger, et al.
Published: (2024-02-01) -
Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
by: Taku Fujimura, et al.
Published: (2019-09-01) -
Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance
by: William Wagstaff, et al.
Published: (2022-11-01) -
Systemic Therapy of Metastatic Melanoma: On the Road to Cure
by: Julian Steininger, et al.
Published: (2021-03-01)